ID

34394

Descrizione

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms; ODM derived from: https://clinicaltrials.gov/show/NCT01309789

collegamento

https://clinicaltrials.gov/show/NCT01309789

Keywords

  1. 17/01/19 17/01/19 -
Titolare del copyright

see on clinicaltrials.gov

Caricato su

17 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
Descrizione

ID.1

Tipo di dati

boolean

measurable disease of at least 1.5 cm
Descrizione

ID.2

Tipo di dati

boolean

ecog performance status less than or equal to 2
Descrizione

ID.3

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
Descrizione

ID.4

Tipo di dati

boolean

current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
Descrizione

ID.5

Tipo di dati

boolean

history of another primary malignancy that has not been in remission for at least 3 years
Descrizione

ID.6

Tipo di dati

boolean

left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
Descrizione

ID.7

Tipo di dati

boolean

viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
Descrizione

ID.8

Tipo di dati

boolean

known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
Descrizione

ID.9

Tipo di dati

boolean

Similar models

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
boolean
ID.2
Item
measurable disease of at least 1.5 cm
boolean
ID.3
Item
ecog performance status less than or equal to 2
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
boolean
ID.5
Item
current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
boolean
ID.6
Item
history of another primary malignancy that has not been in remission for at least 3 years
boolean
ID.7
Item
left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
boolean
ID.8
Item
viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
boolean
ID.9
Item
known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
boolean

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial